1346604-70-3

Candesartan-d₄ is intended for use as an internal standard for the quantification of candesartan by GC- or LC-MS. Candesartan is an antagonist of the angiotensin II type 1 (AT₁) receptor (K_is = 0.17, 0.12, and 0.12 nM for human AT₁, rat AT_1A, and rat AT_1B recombinant receptors, respectively) and an active metabolite of the prodrug candesartan cilexitil (Item No. 10489). It is selective for AT₁ over AT₂ receptors (K_i = 26,500 nM for the human recombinant AT₂ receptor). It inhibits angiotensin II-induced contraction of isolated rabbit aortic strips and increases in blood pressure in rats following intravenous administration (ID₅₀ = 0.033 mg/kg). Formulations containing candesartan have been used in the treatment of hypertension and heart failure.

CANDESARTAN-D4 is White to Off-White Solid

CANDESARTAN-D4 is  an angiotensin II type-1 receptor antagonist. Used in treatment of congestive heart failure. Antihypertensive.

[1] Y. INADA  S. C  T Nakane*. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors[J]. Fundamental & Clinical Pharmacology, 2002, 16 4: 317-323. DOI: 10.1046/j.1472-8206.2002.00076.x
[2] Y SHIBOUTA. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2’-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2’-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).[J]. Journal of Pharmacology and Experimental Therapeutics, 1993, 266 1: 114-120.